Abstract: Tumor-Treating Fields elicit a conditional vulnerability to PARP inhibitors (e.g., Olaparib) in certain cancer cells such as non-small cell lung cancer (NSCLC) cell lines. This conditional vulnerability is exploited in a method of killing cancer cells that comprises delivering a PARP inhibitor to the cancer cells and applying an alternating 80-300 kHz electric field to the cancer cells. At least a portion of the applying step is performed simultaneously with at least a portion of the delivering step. In some embodiments, an additional step of treating the cancer cells with a radiation therapy is added to the method. In some embodiments, the frequency of the alternating electric field is between 100 and 200 kHz.
Type:
Application
Filed:
April 1, 2025
Publication date:
August 14, 2025
Applicant:
Board of Regents of the University of Texas System
Inventors:
Michael STORY, Debabrata SAHA, Narasimha Kumar KARANAM
Abstract: A method and apparatus for radiation therapy using functional measurements of branching structures. The method includes determining a location of each voxel of a plurality of voxels in a reference frame of a radiation device. The method further includes obtaining measurements that indicate a tissue type at each voxel. The method further includes determining a subset of the voxels based on an anatomical parameter of a respective branching structure of a set of branching structures indicated by the measurements. The method further includes determining a subset of the voxels that enclose an organ-at-risk (OAR) volume. The method further includes determining a value of a utility measure at each voxel. The method further includes determining a series of beam shapes and intensities which minimize a value of an objective function based on a computed dose delivered to each voxel and the utility measure for that voxel summed over all voxels.
Type:
Grant
Filed:
February 7, 2023
Date of Patent:
July 29, 2025
Assignees:
University Of Maryland, Baltimore, The Board of Regents of the University of Texas System, Broncus Medical Inc.
Inventors:
Amit Sawant, Robert Timmerman, Yulong Yan, Henky Wibowo, Esther Vicente, Arezoo Modiri
Abstract: The present disclosure relates to degradable polymers which contain a hydrophobic and hydrophilic segment which is sensitive to pH. In some aspects, the polymers form a micelle which is sensitive to pH and have backbones which are capable of undergoing degradation in vivo. In some aspects, the disclosure also provides methods of using these degradable polymers for the delivery of a drug.
Type:
Grant
Filed:
June 22, 2020
Date of Patent:
July 22, 2025
Assignee:
The Board of Regents of The University of Texas System
Inventors:
Jinming Gao, Xu Wang, Houliang Tang, Wei Li, Jonathan Wilhelm, Baran Sumer
Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.
Type:
Application
Filed:
January 16, 2025
Publication date:
July 17, 2025
Applicant:
The Board of Regents of The University of Texas System
Inventors:
Qiang CHENG, Tuo WEI, Daniel J. SIEGWART
Abstract: In some aspects, the present disclosure provides compositions of lipid nanoparticles useful for the delivery of large RNAs including mRNAs. These compositions may include a cationic ionizable lipid, a phospholipid, a PEGylated lipid, and a steroid including using less of a cationic ionizable lipid than compositions with shorter nucleic acids. These compositions may be used to treat a disease or disorder for which the delivery of an mRNA is therapeutically effective.
Type:
Grant
Filed:
June 14, 2024
Date of Patent:
July 15, 2025
Assignee:
The Board of Regents of The University of Texas System
Abstract: The present disclosure describes a new native peptide designated herein as Dwarf Open Reading Frame, or DWORF. This peptide enhances the apparent activity of the SERCA pump, is positively inotropic and lusitropic, and therefore is provided as a therapeutic agent for disorders characterized by cytosolic calcium overload.
Type:
Grant
Filed:
August 2, 2021
Date of Patent:
July 8, 2025
Assignee:
The Board of Regents of The University of Texas System
Inventors:
Eric N. Olson, Rhonda S. Bassel-Duby, Catherine A. Makarewich, Benjamin R. Nelson
Abstract: Disclosed herein are methods of synthesizing compounds of the formula wherein the variables are defined herein. Also provided are compounds produced using these methods. In some aspects, the methods provided herein may be used to create di- and tri-substituted BCPs.
Type:
Application
Filed:
March 17, 2023
Publication date:
July 3, 2025
Applicant:
The Board of Regents of The University of Texas System
Abstract: Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein.
Type:
Grant
Filed:
November 21, 2019
Date of Patent:
June 24, 2025
Assignees:
Rodeo Therapeutics Corporation, Case Western Reserve University, Board of Regents of the University of Texas System
Inventors:
Sanford Markowitz, Joseph Ready, Stephen L. Gwaltney, II, Monika Antczak
Abstract: The present invention relates to assays, methods, and kits to assess traumatic brain injury (TBI) in a subject. The present invention also relates to ultrasensitive assays for GFAP, tau, CKBB, IL-1?, IL-2, IL-6, IL-10, IL-22, IP-10, TNF?, TSLP, NFL, and/or NFH.
Type:
Grant
Filed:
March 8, 2019
Date of Patent:
June 24, 2025
Assignees:
Meso Scale Technologies, LLC., Georgetown University, The Board of Regents of the University of Texas System
Inventors:
Jeff Debad, Joshua Gatson, Mark Burns, Arianna Biesso
Abstract: Processes that determine transcriptional regulation from genetic sequence data are described. Generally, computational models are trained to predict transcriptional regulatory effects, which can be used in several downstream applications. Various methods further develop research tools, develop and perform diagnostics, and treat individuals based on identified variants.
Type:
Application
Filed:
June 21, 2022
Publication date:
June 5, 2025
Applicants:
The Trustees of Princeton University, The Simons Foundation, Inc., The Board of Regents of The University of Texas System
Inventors:
Olga G. Troyanskaya, Kathleen Chen, Jian Zhou
Abstract: Embodiments of the present disclosure provide robotic systems, apparatuses, and methods. One such robotic system comprises a robotic surgical tool; and a steering system configured to steer the robotic surgical tool based on motion angle commands along X and Y axes as the robotic surgical tool moves in an Z axis direction within a tubular passageway. The system further comprises a computing device that executes an artificial intelligence program configured to control the steering system by computing the motion angle commands based on a current position of the robotic surgical tool along planar axes of the tubular passageway and center positions of the passageway along the planar axes. Other systems and methods are disclosed.
Type:
Grant
Filed:
February 12, 2021
Date of Patent:
June 3, 2025
Assignee:
Board of Regents of the University of Texas System
Inventors:
Amir Jafari, Miltiadis Alamaniotis, Teja Guda, Dimitrios Miserlis
Abstract: The present disclosure relates to, among other things, antibody-drug conjugates comprising a STING agonist cyclic di-nucleotide conjugated to an antibody, preparation methods therefor, and uses therefor.
Type:
Grant
Filed:
December 16, 2021
Date of Patent:
May 27, 2025
Assignees:
ImmuneSensor Therapeutics, Inc., The Board of Regents of the University of Texas System
Abstract: The present disclosure provides compounds that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.
Type:
Grant
Filed:
March 2, 2023
Date of Patent:
April 22, 2025
Assignees:
Immunesensor Therapeutics, Inc., The Board of Regents of The University of Texas System
Inventors:
Qi Wei, Heping Shi, Matt Tschantz, Jian Qiu, Youtong Wu, Huiling Tan, Lijun Sun, Chuo Chen, Zhijian Chen
Abstract: Sensors employing elastomers enhanced with electrically conductive 2D nanoparticles are provided. The nanoparticles are formed by applying shear to layered materials present in elastomer precursors (e.g., elastomeric monomer(s) and/or curing agent(s)). Subsequent exfoliation of the layers occurs directly within the precursor and/or curing agent. The cured elastomer nanocomposites can be employed for electrochemical sensing, flexible touchpads, pressure sensors, and wireless sensors, amongst other applications.
Type:
Application
Filed:
September 6, 2024
Publication date:
April 3, 2025
Applicants:
Rutgers, The State University of New Jersey, The Board of Regents of The University of Texas System
Inventors:
Jennifer K. Lynch-Branzoi, Ali Ashraf, Ashiqur Rahman, Nazmul Islam
Abstract: A method is provided for distinguishing between and/or diagnosing Parkinson's disease (PD) or multiple system atrophy (MSA) in a subject who is exhibiting symptoms associated with both PD and MSA. The method comprises: (A) contacting a biological sample obtained from the subject and comprising soluble, misfolded alpha-synuclein (?S) protein with a pre-incubation mixture comprising a monomeric ?S substrate and an indicator to form an incubation mixture; (B) conducting an incubation cycle two or more times on the incubation mixture to form misfolded ?S aggregates; (C) subjecting the incubation mixture to excitation and detecting via indicator fluorescence emission the misfolded ?S aggregates; and (D) diagnosing the subject has having PD or MSA depending on the fluorescence emission intensity. In some aspects, the incubation cycles are conducted in the presence of a bead.
Type:
Grant
Filed:
January 21, 2021
Date of Patent:
April 1, 2025
Assignees:
Board of Regents of the University of Texas System, Amprion, Inc.
Inventors:
Claudio Soto Jara, Mohammad Shahnawaz, Luis Concha
Abstract: The present techniques may provide improved processing and functionality of performance of the 128-bit AES Algorithm, which may provide improved power consumption. For example, in an embodiment, an encryption and decryption apparatus may comprise memory storing a current state matrix of an encryption or decryption process and a plurality of multiplexers configured to receive from the memory current elements of the state matrix stored in the memory, perform a cyclic shift on the received elements of the state matrix, and transmit the shifted elements to the memory for storage as a new state matrix.
Type:
Grant
Filed:
November 30, 2023
Date of Patent:
March 25, 2025
Assignee:
The Board of Regents of the University of Texas System
Abstract: Described herein are methods and systems for identifying and/or treating subjects having cancer who are more likely to respond to treatment with an inhibitor of the transcription factor HIF-2?.
Type:
Application
Filed:
December 2, 2024
Publication date:
March 20, 2025
Applicant:
The Board of Regents of The University of Texas System
Inventors:
Min Soo KIM, James BRUGAROLAS, Tae Hyun HWANG, Yang XIE
Abstract: Provided herein are compositions comprising multi domain peptide (MDP) hydrogels where the peptides that constitute the hydrogel have at least one N6-(1-iminoethyl)-lysine side chain. Also provided are hydrogels that further comprise a STING agonist, an immune checkpoint inhibitor, and/or an anti-cancer therapy. Also provided are methods of using such compositions in the treatment of cancer.
Type:
Grant
Filed:
December 18, 2020
Date of Patent:
March 18, 2025
Assignees:
William Marsh Rice University, Baylor College of Medicine, The Board of Regents of The University of Texas System
Inventors:
Jeffrey Hartgerink, Andrew G. Sikora, David Leach, Jared M. Newton, Simon Young
Abstract: The present disclosure provides one or more amino lipids such as an amino lipids containing a sulfonic acid or sulfonic acid derivative of the formulas: wherein the variables are as defined herein. These amino lipids may be used in compositions with one or more helper lipids and a nucleic acid therapeutic agent. These compositions may be used to treat a disease or disorder such as cancer, cystic fibrosis, or other genetic diseases.
Type:
Grant
Filed:
May 10, 2023
Date of Patent:
March 18, 2025
Assignee:
The Board of Regents of The University of Texas System